Medication info
Dapaone M Extended-Release Tablet 10/1000 milligrams

Dapaone M Extended-Release Tablet 10/1000 milligrams

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›1010mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Yellow or dark yellow bilaterally convex oval film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202204123 · Approved 2022.11.16 · Insurance code 671807570

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same dose of metformin the patient was taking or an appropriately adjusted dose therapeutically close to it. When converting from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When converting from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Because such a switch may cause changes in glycemic control, any change in treatment of patients with type 2 diabetes should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function tends to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used as an adjunct to diet and exercise to help control blood sugar in adults with type 2 diabetes. It specifically aids in effectively lowering blood sugar when dapagliflozin and metformin are administered together. Furthermore, for type 2 diabetes patients who do not achieve sufficient blood sugar control and have cardiovascular disease or risk factors, it's necessary to refer to the expert's attention regarding the cardiovascular impact of dapagliflozin. This medication contributes to improved blood sugar control and the prevention of diabetes-related complications.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same dose of metformin the patient was taking or an appropriately adjusted dose therapeutically close to it. When converting from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When converting from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Because such a switch may cause changes in glycemic control, any change in treatment of patients with type 2 diabetes should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function tends to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).

Precautions

This medication can very rarely cause a serious condition known as lactic acidosis, so attention should be paid to these symptoms. Care should be taken as hypoglycemia may occur when used with other diabetes medications. Patients with severely impaired kidney function or conditions affecting the kidneys such as dehydration or severe infections should not use this medication. Pregnant or nursing women should also refrain from taking this medication. Elderly patients or those with slightly impaired kidney function should regularly monitor kidney function and fluid status while using this medication. This medication may increase the risk of genital and urinary tract infections, so if signs of infection occur, consult healthcare professionals immediately. Prolonged use may lead to vitamin B12 deficiency, so it is advisable to check blood levels if taking for an extended period. If planning for surgery or radiological imaging with contrast agents, discontinue this medication in advance and restart after confirming normal kidney function. Alcohol may increase the risk of side effects associated with this medication; therefore, excessive drinking should be avoided during use. Dizziness or hypotension may occur while taking this medication, so caution is needed when driving or operating machinery. If any unusual symptoms occur while taking this medication, consult a doctor immediately for appropriate measures.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lumbar pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignancy
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbance
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinopathy
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the efficacy of the medication.

Appearance and packaging

Appearance

Yellow or dark yellow bilaterally convex oval film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.